# Oxaliplatin-Induced Pulmonary Fibrosis: A Rare but Fatal Reality

## TL;DR

Oxaliplatin, a chemotherapy drug, can cause a rare but deadly lung condition called interstitial lung disease, which requires early detection and treatment.

## Contribution

Highlights the rare but severe side effect of oxaliplatin-induced pulmonary fibrosis and emphasizes the need for early diagnosis and management.

## Key findings

- Oxaliplatin-induced ILD is a rare but potentially fatal condition linked to chemotherapy.
- Early detection and stopping oxaliplatin therapy improve patient outcomes.
- Corticosteroids and oxygen therapy are common treatments for this condition.

## Abstract

Oxaliplatin is a commonly used chemotherapy drug for the treatment of gastrointestinal malignancies, but it can lead to various side effects, including interstitial lung disease (ILD), a rare but potentially fatal condition. ILD is an inflammatory and fibrotic lung disease that can cause progressive lung damage and respiratory failure. The exact mechanism by which oxaliplatin induces ILD is not known, but it is believed to be due to an immune-mediated response, or direct toxicity via oxidative stress. The symptoms of oxaliplatin-induced ILD include cough, shortness of breath, fatigue, and weight loss. Diagnosis of oxaliplatin-induced ILD requires a high index of suspicion, and imaging tests such as chest X-rays and CT scans are used to confirm the diagnosis. Treatment options for oxaliplatin-induced ILD include corticosteroids, oxygen therapy, and early cessation of oxaliplatin therapy. Early detection and prompt management are crucial to improve the prognosis of patients with oxaliplatin-induced ILD.